Status:
TERMINATED
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
Lead Sponsor:
ConjuChem
Conditions:
Obesity
HIV Infections
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This is a multicenter, randomized, placebo-controlled, double-blind, Phase 2 study. Patients will be treated for a total of 12 weeks. There will be a 6 week follow-up period after the treatment period...
Eligibility Criteria
Inclusion
- Age 18-65 on stable antiviral regimen
- Documented HIV infection
- HIV associated visceral obesity
- Body mass index (BMI) \> 24 and \< 30 kg/m2
Exclusion
- Diabetes
- Use of growth hormone (GH) or other GH secretagogues
- Use of systemic glucocorticoids,
- Use of megestrol acetate or other appetite stimulants,
- Use of general anorexigenic or weight-reducing agents, or
- Use of androgens, other than testosterone replacement therapy for male hypogonadism at physiological doses and on a stable regimen for at least 6 months prior to randomization.
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00267527
Start Date
December 1 2005
End Date
September 1 2006
Last Update
October 16 2006
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.